Clinical trial
Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
NCT01502956 is registered in ClinicalTrials.gov with NICHD Pelvic Floor Disorders Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
- Lead sponsor
- NICHD Pelvic Floor Disorders Network
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 29, 2012
- Completion date
- July 31, 2016
- Enrollment
- 386 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.